



ASX RELEASE

13 February 2009

Tissue Therapies despatches Prospectus today

Tissue Therapies Limited (**Tissue Therapies**) despatched the Prospectus (and Supplementary Prospectus) for its non-renounceable rights issue to raise up to \$3.4 million to shareholders today. The Prospectus was lodged with ASIC and ASX Limited on 28 January 2009 and the Supplementary Prospectus was lodged with ASIC and ASX Limited on 3 February 2009.

Further information: Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: 07 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic ulcers and burns,

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com